Treatment of advanced small cell lung cancer. Clinical case and literature review

Lung cancer is one of the most common tumors in humans. The incidence is in one of the leading positions. In 2019 1327 patients with this pathology were identified in the Republic of Bashkortostan. Of these, with stage III of the disease 28.7%, with stage IV 45.8%, which is higher. Small cell lung...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Konstantin V. Menshikov, Aleksandr V. Sultanbaev, Shamil I. Musin, Irina A. Menshikova, Ainur F. Nasretdinov, Nadezda I. Sultanbaeva
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	small cell lung cancer immunotherapy chemotherapy atezolizumab impower133 overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/84b8fb205d4b4a0d9e375fb79bab01f4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:84b8fb205d4b4a0d9e375fb79bab01f4
record_format	dspace
spelling	oai:doaj.org-article:84b8fb205d4b4a0d9e375fb79bab01f42021-11-30T16:55:01ZTreatment of advanced small cell lung cancer. Clinical case and literature review1815-14341815-144210.26442/18151434.2021.1.200726https://doaj.org/article/84b8fb205d4b4a0d9e375fb79bab01f42021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70357/51291https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Lung cancer is one of the most common tumors in humans. The incidence is in one of the leading positions. In 2019 1327 patients with this pathology were identified in the Republic of Bashkortostan. Of these, with stage III of the disease 28.7%, with stage IV 45.8%, which is higher. Small cell lung cancer (SCLC) is one of the most prognostically unfavorable malignant tumors in humans. About 15% of lung tumors are SCLC. The first combination for the treatment of advanced SCLC after etoposide and platinum preparations was the combination of the etoposide + carboplatin (EP) regimen with atezolizumab. In the IMpower133 study, after a median follow-up of 13.9 months. median overall survival in the atezolizumab group was 12.3 months, and in the placebo group 10.3 months. In clinical observation, the effectiveness of the combination of the EP regimen with atezolizumab has been demonstrated. A patient with SCLC received 4 courses of EP therapy with atezolizumab and 14 injections of atezolizumab. The partial response achieved is retained. Case study efficacy and satisfactory safety profile of the combination of atezolizumab and the EP regimen.Konstantin V. MenshikovAleksandr V. SultanbaevShamil I. MusinIrina A. MenshikovaAinur F. NasretdinovNadezda I. SultanbaevaIP Habib O.N.articlesmall cell lung cancerimmunotherapychemotherapyatezolizumabimpower133overall survivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 112-115 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	small cell lung cancer immunotherapy chemotherapy atezolizumab impower133 overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	small cell lung cancer immunotherapy chemotherapy atezolizumab impower133 overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Konstantin V. Menshikov Aleksandr V. Sultanbaev Shamil I. Musin Irina A. Menshikova Ainur F. Nasretdinov Nadezda I. Sultanbaeva Treatment of advanced small cell lung cancer. Clinical case and literature review
description	Lung cancer is one of the most common tumors in humans. The incidence is in one of the leading positions. In 2019 1327 patients with this pathology were identified in the Republic of Bashkortostan. Of these, with stage III of the disease 28.7%, with stage IV 45.8%, which is higher. Small cell lung cancer (SCLC) is one of the most prognostically unfavorable malignant tumors in humans. About 15% of lung tumors are SCLC. The first combination for the treatment of advanced SCLC after etoposide and platinum preparations was the combination of the etoposide + carboplatin (EP) regimen with atezolizumab. In the IMpower133 study, after a median follow-up of 13.9 months. median overall survival in the atezolizumab group was 12.3 months, and in the placebo group 10.3 months. In clinical observation, the effectiveness of the combination of the EP regimen with atezolizumab has been demonstrated. A patient with SCLC received 4 courses of EP therapy with atezolizumab and 14 injections of atezolizumab. The partial response achieved is retained. Case study efficacy and satisfactory safety profile of the combination of atezolizumab and the EP regimen.
format	article
author	Konstantin V. Menshikov Aleksandr V. Sultanbaev Shamil I. Musin Irina A. Menshikova Ainur F. Nasretdinov Nadezda I. Sultanbaeva
author_facet	Konstantin V. Menshikov Aleksandr V. Sultanbaev Shamil I. Musin Irina A. Menshikova Ainur F. Nasretdinov Nadezda I. Sultanbaeva
author_sort	Konstantin V. Menshikov
title	Treatment of advanced small cell lung cancer. Clinical case and literature review
title_short	Treatment of advanced small cell lung cancer. Clinical case and literature review
title_full	Treatment of advanced small cell lung cancer. Clinical case and literature review
title_fullStr	Treatment of advanced small cell lung cancer. Clinical case and literature review
title_full_unstemmed	Treatment of advanced small cell lung cancer. Clinical case and literature review
title_sort	treatment of advanced small cell lung cancer. clinical case and literature review
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/84b8fb205d4b4a0d9e375fb79bab01f4
work_keys_str_mv	AT konstantinvmenshikov treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview AT aleksandrvsultanbaev treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview AT shamilimusin treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview AT irinaamenshikova treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview AT ainurfnasretdinov treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview AT nadezdaisultanbaeva treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview
_version_	1718406455697080320

Treatment of advanced small cell lung cancer. Clinical case and literature review

Ejemplares similares